Alnylam Pharmaceuticals Stock News

These biotech stocks could be worth watching in 2022.

(RTTNews) - Alnylam Pharmaceuticals, Inc. (ALNY) announced a collaboration with Novartis to leverage Alnylam''s siRNA technology to inhibit a target discovered at the Novartis Institutes for BioMedical Research, potentially leading to development of a treatment designed to promote the regrowth of functional liver cells and to provide an

Alnylam Pharmaceuticals (ALNY) announces a collaboration with Novartis (NVS) to leverage its proven, proprietary siRNA technology to inhibit a target discovered at the Novartis

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 40th Annu

We discuss a few companies like BioMarin (BMRN), Adaptimmune (ADAP), CRISPR Therapeutics (CRSP), and Alnylam Pharmaceuticals (ALNY) with solid product portfolios, deep pipelines which make them attrac

Alnylam Pharmaceuticals Inc (ALNY) shares closed today 17.1% lower than it did at the end of yesterday. The stock is currently up 24.0% year-to-date, up 17.1% over the past 12 months, and up 292.6% over the past five years. Today, the Dow Jones Industrial Average rose 1.0%, and the S&P 500 rose 1.4%. Trading Activity Shares traded as high as $199.88 and as low as $159.11 this week.Shares closed 24.0% below its 52-week high and 29.9% above its 52-week low.Trading volume this week was 78.0% lower than the 10-day average and 59.6% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and beats it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -312.3% The company's stock price performance over the past 12 months beats the peer average by -233.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

This expansion is attributed to a growing older population, rising healthcare expenditures, and an increase in the incidence of cancer and other chronic diseases. Revenue inflow will be aided by advancements in cancer medication discovery, more investments in the industry,

Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novartis Receives FDA Nods For Arthritis Treatment And Cholesterol Drug Novartis AG (NYSE: NVS ) announced the U.S. Food and Drug Administration has approved Cosentyx for the treatment of active enthesitis-related arthritis in patients four years and older, and active psoriatic arthritis in patients two years and older. Cosentyx is now the first biologic indicated for ERA and the only biologic treatment approved for both ERA and PsA in pediatric patients in the U.S., the company said. Separately, the company announced FDA approval of Leqvio, the first and only small interfering RNA therapy to lower low-density lipoprotein cholesterol, with two doses a year, after an initial dose and one at three months. Leqvio has been licensed from Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) by the Medicines Company, which has since then been acquired by Novartis. Novartis shares were up 0.54% at $86.78 in premarket trading.

The "RNAi for Therapeutic" Market report offers qualitative and quantitative insights and a detailed analysis of market size & growth rate for all possible segments in the market. The Global RNAi for Therapeutic Industry presents a market overview, product details,

The FDA has approved Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) Leqvio (inclisiran) to lower low-density lipoprotein cholesterol (LDL-C).  Leqvio is indicated in the U.S. as an adjunct to diet a

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administrations (FDA) approval of Leqvio® (inclisiran), the fourth small interfering RNA (siRNA) therapy (or RNAi therapeutic) approved in the U.S., and the first and only to lower low-density lipoprotein cholesterol (also known as bad cholesterol or LDL-C). Leqvio is indicated in the U.S. as an adjunct to diet an

Related Stocks: PXD , FTV , UTZ , EXPE , TWTR , CMI , NVAX , RYAN , ALNY , FOUR , EPAM , DISCA , WYNN , AVLR , AGIO , SPG , PINS , WING ,

Related Stocks: VRSK , MKC , UNP , BA , MRNA , ALNY , AFRM , SHOP , DLO , TOST , GPN , BMY , AI ,

Wall Street brokerages expect Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to post sales of $232.16 million for the current quarter, Zacks Investment Research reports. Seven analysts have made estimates for Alnylam Pharmaceuticals earnings, with estimates ranging from $214.75 million to $244.40 million. Alnylam Pharmaceuticals posted sales of $163.56 million in the same quarter last year, which would []